Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease
NL-OMON59783Phase 1Suspended
- Sponsor
- GSK
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of GSK4771261 in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by GSK. Started Nov 2025; status: suspended.
02
Drugs
GSK4771261
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON59783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59783.